Leading aesthetic company Galderma is set to acquire Alastin Skincare, one of the fastest-growing, physician-dispensed skin care brands in the U.S. The deal looks to enhance Galderma’s integrated dermatology platform.

Founded in 2015, Alastin’s portfolio of high-growth, peri-procedural products are deemed “highly-synergistic” with Galderma, and Alastin’s patented TriHex Technology, a proprietary blend of peptides and active botanicals to support the appearance of rejuvenated skin, looks to enhance Galderma’s premium aesthetics portfolio. Since the brand launched, Alastin has delivered “rapid and consistent sales growth, achieving a CAGR of 106 percent between 2016 and 2020,” according to Galderma statement.

Galderma will leverage its global reach and integrated dermatology platform to take Alastin into its next growth phase.

Formerly a subsidiary of L’Oréal and Nestle, Nestle sold Galderma for $10.2 billion to a consortium comprising EQT VIII fund, Luxinva (a wholly owned subsidiary of Abu Dhabi Investment Authority), PSP Investments and other institutional investors. Since then, it has been the largest independent dermatology company in the world.